CELL INTELLIGENCE · 肿瘤细胞治疗研究

免疫缺失作为人乳头瘤病毒相关宫颈癌根治性治疗后延迟复发的拟议框架

Immune Absence as a Proposed Framework for Delayed Relapse After Curative-Intent Treatment in Human Papillomavirus-Associated Cervical Cancer.

子宫颈 I 期神经内分泌肿瘤中的免疫细胞密度、HLA 状态和 PD-L1 表达

Immune cell densities, HLA status, and PD-L1 expression in stage I neuroendocrine neoplasm of the uterine cervix.

靶向 EGFR 的配体基 CAR-T 细胞对妇科恶性肿瘤表现出良好的抗肿瘤效应

Ligand-Based CAR-T Cells Targeting EGFR Exhibit Favorable Antitumor Effects Against Gynecologic Malignancies.

宫颈癌免疫治疗的最新进展

Recent advances in immunotherapy for cervical cancer.

免疫检查点抑制剂治疗复发性子宫颈癌诱发细胞因子释放综合征：一例病例报告

Cytokine release syndrome induced by immune checkpoint inhibitor treatment for uterine cervical cancer recurrence: A case report.

宫颈癌中 Trop-2 表达与肿瘤免疫微环境

Trop-2 expression and the tumor immune microenvironment in cervical cancer.

宫颈癌中 Trop-2 的表达与瘤内 TILs 水平升高相关，提示 Trop-2 靶向治疗单独或联合免疫检查点抑制剂具有潜在应用价值。

蛋白酶激活受体 1（PAR1）表达与 HPV 相关口咽癌预后相关

Protease-Activated Receptor 1 (PAR1) Expression Contributes to HPV-Associated Oropharyngeal Cancer Prognosis.

我们的结果表明，PAR1 表达影响 HPV 相关口咽癌的预后和复发率。

接受放疗的宫颈癌中肿瘤突变负荷、间质 CD8⁺ TIL（肿瘤浸润淋巴细胞）与临床因素的关联

Association between Tumor Mutational Burden, Stromal CD8(+) Tumor-Infiltrating Lymphocytes, and Clinical Factors in Cervical Cancers Treated with Radi

这些数据表明 TMB 与 CD8+ TIL 密度的独立性，以及 ARID1A 改变参与接受放疗的宫颈癌患者的抗肿瘤免疫反应，值得进一步的机制研究和前瞻性验证。